Rezafungin?

Rezafungin is a next‑generation echinocandin antifungal that has been studied for candidemia and invasive fungal infections. Here’s a concise overview:

- What it is: A member of the echinocandin class with a long half‑life designed to allow once‑weekly IV dosing.

- Mechanism of action: Inhibits 1,3‑β‑D‑glucan synthase, impairing fungal cell wall synthesis and causing cell lysis.

- Spectrum (key points):
- Active against many Candida species (including some azole‑resistant strains and Candida auris).
- Activity against Aspergillus spp reported in trials.
- Generally not active against Cryptococcus spp.
- Like other echinocandins, resistance can occur primarily via FKS mutations, reducing susceptibility.

- Pharmacokinetics and dosing implications:
- Long half‑life with dosing strategies studied as loading doses followed by once‑weekly maintenance dosing.
- IV only; largely hepatically cleared with limited drug–drug interaction potential (less CYP involvement than some other antifungals).

- Clinical status and use:
- Rezafungin has been in Phase 3 development for candidemia and invasive candidiasis and for other invasive fungal infections.
- As of mid‑2024, it had not yet achieved FDA approval in the United States (regulatory status varies by country and may have changed since then).

- Safety and tolerability (general class notes):
- Overall, echinocandins are generally well tolerated.
- Possible adverse effects include infusion‑related reactions, hepatotoxicity (rare), GI symptoms, and hypersensitivity in some patients.
- Interactions are usually limited, given the class’s minimal CYP involvement.

- Resistance considerations:
- Resistance linked to FKS gene mutations; cross‑resistance can occur among echinocandins in some strains.

If you’d like, tell me:
- Are you asking from a clinician, patient, or researcher perspective?
- Which region/country’s regulatory status matters to you?
- Do you want dosing examples, comparisons to other echinocandins (eg, micafungin, caspofungin, anidulafungin), or discussion of specific Candida/Aspergillus scenarios? I can tailor the briefing accordingly.